Geisinger High-Risk Osteoporosis Clinic: Narrowing Post-Fracture Care Gaps and Lessons Learned

Main Article Content

Thomas P. Olenginski, MD


Background: In 2008, Geisinger Rheumatology established a Fracture Liaison Service (FLS) termed HiROC (High-Risk Osteoporosis Clinic). Inpatient HiROC teams integrated with outpatient HiROC clinics.

Aim: We review the history of Geisinger HiROC, performance and lessons learned. We examine this: In a high-risk, post-fracture, drug-indicated patient without treatment contraindications, was patient treated? If a patient chose followup with Geisinger primary care physician (PCP), was that patient treated?

Results: Four Geisinger HiROC analyses are presented: 2008-2011; 2013-2015;2016; and 2017-2018. HiROC treatment rates are 80 %, 75.4 %, 74 %, and 72 %, respectively. Geisinger PCP treatment rates are 32.2 %, 13.8 %, and 14 %. (PCP data from 2017-2018 not included) 2008-2011 analysis included 888 patients, mean age 76.1, 77.6 % women and 22.4 % men. Mean 25-OH Vit. D was 25.6. Hip fractures represented 58.2 % of cohort and vertebral fractures (VF) 11.6 %. At discharge, 44.3 % went to Rehab, 31.5 % to Nursing Home (NH) and 24 % home. Six- month mortality was 14.7 % and HiROC followup 51.5 %.

2013-2015 analysis included 1279 patients with mean age of 77.8 and 74 % women, 26 % men. Hip fractures were seen in 67.6 % and VF in 6.6 % and mean 25-OH Vit. D was 25.8. Patients chose HiROC 42.6 %, 37 % HiROC patients were lost to followup, and 6 month mortality was 16 %. GHP insured 27.4 % and within GHP-insured patients, HiROC treated 74.7 % versus 19.7 % by Geisinger PCP. In 2016, we reported 380 patients, mean age 78, 69 % women, 31 % men. Hip fractures accounted for 74.5 %, VF 6.6 %, with mean 25-OH Vit.D 25.8 and 17 % six month mortality. Patients chose HiROC 46 % of time.

2017-2018 analysis included 740 patients, mean age 78, with 89 % women and 11 % men. Hip fractures accounted for 78 % and VF 6.6 %. HiROC was chosen by 45 % patients and 6-month mortality was 14 %.

Conclusions: Geisinger HiROC treated high-risk, post-fractured, drug indicated patients 72 – 80 % of time, far superior to Geisinger PCP rates of 13.8 - 32.2 %.

Keywords: Osteoporosis, Osteoporosis Clinic, Geisinger High-Risk Osteoporosis Clinic, Post-Fracture Care Gaps, Post-Fracture Care Gaps and Lessons Learned, High-Risk Osteoporosis, High-Risk Osteoporosis Clinic

Article Details

How to Cite
OLENGINSKI, Thomas P.. Geisinger High-Risk Osteoporosis Clinic: Narrowing Post-Fracture Care Gaps and Lessons Learned. Medical Research Archives, [S.l.], v. 11, n. 1, jan. 2023. ISSN 2375-1924. Available at: <>. Date accessed: 16 july 2024. doi:
Research Articles


1. Giangregorio L, Papaioannou A, Cranney A, Zytaruk N, Adachi JD. Fragility fractures and the osteoporosis care gap: An international phenomenon. Semin Arthritis Rheum. 2006 Apr; 35 (5):293-305
2. Fraser LA, Ioannidis G, Adachi JD et al. Fragility fractures and the osteoporosis care gap in woman: the Canadian mulicentre osteoporosis study. Osteoporos Int. 2011 Mar:22(3);789-796.
3. Papaioannou A, Kennedy CC, Ioannidis et al. The osteoporosis care gap in men with fragility fractures: the Canadian multicentre osteoporosis study. Osteoporos Int. 2008 Apr;19(4):581-7.
4. Singer, A, Allmen T, Battaglino B . New national survey reveals 82 percent of postmenopausal women miss critical connection between osteoporosis and bone fractures. BHOF in the news, Aug 10, 2017.
5. McCloskey E, Rathi J, Heijmas S et al. The osteoporosis treatment gap in patients at risk of fracture in European primary care: a multi-country cross-sectional observational study. Osteoporos Int. 2021 Feb;32(2):251-259
6. Cooper C and Reginster JY. Focus on secondary fracture prevention at the virtual WCO-IOF-ESCEO. IOF Capture the Fracture. Feb 24, 2022.
7. Onkka P, Khandelwal S, Shakoor N, Block J, Fogg L. THU0661 Osteoporosis screening, primary prevention, and treatment in glucocorticoid treated individuals with rheumatic disease. Annals of the Rheumatic Diseases. 2018; 77;524-525.
8. Newman ED, Olenginski T, Perruquet JL, Hummel J, Indeck C and Wood, GC. Using mobile DXA to improve access to osteoporosis care. Journal of Clinical Densitometry 2004:7:71-75.
9. Oppermann B, Ayoub W, Newman ED, Wood GC, Olenginski T. Consultative DXA reporting improves guideline driven quality of care – Implications for increasing DXA reimbursement. Journal of Clinical Densitometry 2010; 13:315-9.
10. Newman ED, Matzko CK, Olenginski TP, et al. Glucocorticoid-induced osteoporosis program (GIOP): a novel, comprehensive, and highly successful care program with improved outcomes at 1 year. Osteoporos Int. 2006;17(9):1428-1434.
11. Olenginski TP, Maloney-Saxon G, Matzko CK et al. High-risk osteoporosis clinic (HiROC): Improving osteoporosis and postfracture care with an organized, programmatic approach. Osteoporos Int. 2015;26(2):801-810.
12. Gallagher C, Vasilakis N, Javaid K. Fracture liaison services in England and Wales, inequity of access and quality of care after a fragility fracture. Clin Med (Lond) 2019;19(suppl 2):77.
13. Chesser T, Javaid MK, Mohsin Z et al. Overview of fracture liaison services in the UK and Europe: standards, model of care, funding and challenges. OTA International 2022; 5, issue 3S: p e198
14. Olenginski TP. Fracture Liaison Service: US perspective. Seibel MJ and Mitchell P. Secondary Fracture Prevention: An International Perspective. 2019, Elsevier, Inc. Chapter 11;155-172.
15. Carlson BC, Robinson WA, Wanderman NR et al. The American Orthopaedic Association’s Own the Bone database: a national quality improvement project for the treatment of bone health in fragility fracture patients. Osteoporos Int. 2018, 29:2101-2109.
16. Akesson K, Marsh D, Mitchell PJ et al. Capture the Fracture: a best practice framework and global campaign to break the fragility fracture cycle. Osteoporos Int. 2013, 24(8):2135-52
17. Compston J. Reducing the treatment gap in osteoporosis. Lancet 2020, Vol. 8, issue 1: pp 7-9.
18. Grossman JM, Gordon R, Ranganath VK et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care and Research. 2010, 62(11):1515-1526.
19. Buckley L, Guyatt G, Fink HA et al. 2017 American College of Rheumatology Guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis and Rheumatology. 2017;69(8):1521-1537.
20. Dunn P, Webb D, Olenginski TP. Geisinger high-risk osteoporosis clinic (HiROC): 2013-2015 FLS Performance Analysis. Osteoporos Int. 2018;29:451-457.
21. Thomas E and Olenginski TP. HiROC Performance Analysis: 2016. Poster presented at Interdisciplinary Symposium on Osteoporosis, May 17-19, 2017, New Orleans LA.
22. Olenginski TP and Mackiewicz K. Geisinger HiROC performance 2017-2018: Continuing to narrow the post-fracture treatment gap. Data presented at American College of Rheumatology annual meeting October 10, 2019, Atlanta GA.
23. Solomon D, Johnston SS, Boytsov NN et al. Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011. J Bone Miner Res 2014;29:1929-1937.
24. Olenginski TP. Measuring impact, improving your program and adjusting to change: what you don’t you until you measure and evaluate. Lecture at Interdisciplinary Symposium on Osteoporosis. May 14, 2016, Miami Fl
25. Khosla S, Amin S, Orwell E. Osteoporosis in men. Endocrine Reviews 2008;29:441-464.
26. Willson T, Nelson SD, Newbold J et al. The clinical epidemiology of male osteoporosis: a review of the recent literature. Clin Epidemiol 2015;7:65-76.
27. Kaufmann JM. Management of osteoporosis in older men. Aging Clinical and Experimental Research 2021,33:1439-1452.
28. Launois R, Cabout E, Benamouzig D et al. Barriers and expectations for patients in post-osteoporotic fracture care in France: The Effel Study. Value in Health. 2022, 25:571-581
29. LeBlanc A, Wang AT, Wyatt K et al. Encounter decision aid vs clinical decision support mor usual care to support patient-centered treatment decisions in osteoporosis: The osteoporosis choice randomized trial II. Plos One 10(5): e0128063.
30. Kolata G. Fearing Drugs’ Rare Side Effects, Millions take their chances with osteoporosis. The New York Times, June 1, 2016
31. Javaid MK, Sami A, Lems W et al. A patient-level key performance indicator set to measure the effectiveness of fracture liaison services and guide quality improvement: a position paper of the IOF Capture the Fracture Working Group, National Osteoporosis Foundation and Fragility Fracture Network. Osteoporos Int. 2020, 31:1193-1204.
32. Cha YH, Ha YC, Park KS, Yoo JII. What is the role of coordinators in the secondary fracture prevention program? Journal of Bone Metabolism 2020;27(3):187-199.
33. Lindsay BR, Olufade, Bauer J et al. Patient-reported barriers to osteoporosis therapy. Arch Osteoporosis 2016; 11(1):19.
34. Simonelli C, Killeen K, Mehle S et al. Barriers to osteoporosis identification and treatment among primary care physicians and orthopedic surgeons. Mayo Clinic Proceedings. 2002;77:334-338.
35. Senay A, Fernandes JC, Delisle J et al. Trajectories of follow-up compliance in a fracture liaison service and their predictors: a longitudinal group-based trajectory analysis. Health Services Research and Managerial Epidemiology 2021;8 –
36. Royal College of Physicians Fracture Liaison Service:
37. Bunta A, Edwards BJ, Macaulay WB et al. Own the Bone, a system-based intervention, improves osteoporotic care after fragility fractures. J Bone Joint Surg Am 2016;98(24):1-8.